Background
The best treatment for patients with pathological stage I-II malignant melanoma (sec AJCC) remains controversial because patients are unlikely to benefit from routine lymphoadenectomy (over treatment risk 80%) in this stage. On the other hand, pitfalls in the identification of occult melanoma are significant (20%). Our objective was to evaluate the single center application of sentinel lymphoadenectomy for the management of early stage melanoma. The sentinel lymph node biopsy (SLN) is a minimally invasive technique of staging the regional lymph nodes for melanoma that balance risks and effectiveness.
Methods
From April 2002 a total of 124 patients with mean age of 56.9 (range 21-90) years, were studied in the multidisciplinary outpatient clinic for melanoma at "Ospedale di Valdagno -ULSS 5". We analyzed 83 patients treated from 2002 through 2008 who underwent SLN biopsy for melanoma. Candidates for SLN are patients with thick primary melanoma (>1 mm sec Breslow) or less if ulcerated or with regression. One day before surgery, lymphoscintigraphy has been performed using 99 mTc-human serum albumin. Intraoperatively, blue dye was injected around the primary site and the nodes were identified using both blue dye and hand-held gamma probe.
Results
Of the 124 patients, 44 were over 65 years old (35.4%); 27 male and 17 female with mean age of 75.3 years (66-90). Primaries were on head/neck (n = 18), trunk (n = 11), upper extremities (n = 7), lower extremities (n = 8). The most common histology was superficial spreading (18) followed by: 11 nodular melanoma, 12 melanoma on lentigo maligna, 1 acral melanoma, 2 metastases of unknown origin. The median tumour thickness was 3.56 mm (0.5-10) and 7 were melanoma ulcerated; 5 melanoma with regression. Among these patients we performed 17 SLN. Metastases in sentinel node were present in 2 cases (11.6%). A man with ulcerated melanoma of the trunk with tumor thickness >5 mm underwent axillaries lymphoadenectomy (25 lymph node removed, 0 metastases) and an 88 year-old female with in-transit metastases (primary knee melanoma) underwent inguinal-crural-otturatory lymphadenectomy (27 nodes removed, 0 metastases). Median hospital stay for the last 2 patients was 5 days and the post-operative course was uneventful.
Conclusion
SLN status is the most important prognostic factor in stage I-II malignant melanoma. Indeed, after 27 months follow-up in 612 SLN-negative patients, disease-free survival was 91%, recurrence rate was 9% and mortality rate was less than 2%. In the SLN-positive group overall survival was 77% and recurrence rate of 33% with a mortality rate of 16%. The procedure helps to identify high-risk recur- 
